{"entity":{"id":"moma-313","kind":"drug","name":"MOMA-313","aka":[],"tldr":"MOMA-313 is an experimental small molecule from MOMA Therapeutics, in phase 1 trials for homologous recombination deficient solid tumours, prostate cancer and pancreatic cancer and other cancers.","summary":"MOMA-313 is a small molecule (oral) from MOMA Therapeutics. A potent and selective oral inhibitor of the helicase domain of DNA polymerase theta (Polθ), which is involved in repairing DNA double-strand breaks; developed alone and with the PARP inhibitor olaparib. Its furthest stage is phase 1, for homologous recombination deficient solid tumours, prostate cancer, pancreatic cancer and breast cancer. ClinicalTrials.gov registers it in one study linked below. NCT06545942 recruiting (registry, checked 3 Nov 2026); first patient dosed August 2024. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"MOMA Therapeutics: momatx.com","url":"https://momatx.com/posts/moma-therapeutics-announces-initiation-of-phase-1-clinical-trial-for-moma-313/"},{"label":"MOMA Therapeutics: momatx.com","url":"https://momatx.com/posts/moma-therapeutics-announces-initiation-of-phase-1-clinical-trial-for-moma-313/"},{"label":"ClinicalTrials.gov: trials of MOMA-313","url":"https://clinicaltrials.gov/search?intr=MOMA-313"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","prostate","pancreatic","breast-cancer","ovarian"],"sections":[],"technologies":[],"targets":["polq"],"drugs":[],"companies":["moma-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06545942"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"MOMA-313","modality":"Small molecule (oral)","mechanism":"A potent and selective oral inhibitor of the helicase domain of DNA polymerase theta (Polθ), which is involved in repairing DNA double-strand breaks; developed alone and with the PARP inhibitor olaparib.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/moma-313/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"polq","kind":"target","name":"POLQ","route":"/targets/polq/"}],"company":[{"id":"moma-therapeutics","kind":"company","name":"MOMA Therapeutics","route":"/companies/moma-therapeutics/"}],"trial":[{"id":"nct06545942","kind":"trial","name":"Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct06545942/"}]}}